Wiener klinische Wochenschrift

, Volume 123, Issue 7–8, pp 199–203 | Cite as

Prognostic value of plasma d-dimer levels in patients with glioblastoma multiforme – Results from a pilot study

  • Matthias HokeEmail author
  • Karin Dieckmann
  • Renate Koppensteiner
  • Martin Schillinger
  • Christine Marosi
  • Wolfgang Mlekusch
Original Article


Glioblastoma multiforme (GBM), the most common primary tumor of the central nervous system, is associated with a state of hypercoagulability. We hypothesized that tumor activity is displayed by elevated d-dimer plasma levels and that d-dimer might be used as a predictor of survival in patients with glioblastoma multiforme. We studied effects on clinical outcomes of d-dimer levels obtained two to three weeks following histologic confirmation of the diagnosis of GBM at surgery or needle biopsy, but prior to chemotherapy or radiation therapy, in 23 patients. During a median follow-up of 7.3 months (interquartile range 3.5 to 22 months), we observed a total of 21 deaths (91.3%). Elevated d-dimer levels were significantly associated with mortality compared to normal values (log rank p = 0.002). The adjusted hazard ratio for death in patients with elevated d-dimer levels was 10.8 (95% confidence interval, 1.3 to 93.1; p = 0.03), compared to controls. Similar effect sizes were revealed when analyzing the association between progression-free survival and d-dimer levels (log rank p = 0.002). Additionally, patients with elevated d-dimer levels were more likely to suffer from venous thromboembolism compared to patients with normal values (log rank p = 0.025). Our data support the assumption that d-dimer levels are related to adverse outcome in patients with GBM. However, our results need to be confirmed by a large, prospective cohort study.


Glioblastoma multiforme D-dimer Survival Progression-free survival Venous thromboembolism 

Die Prognostische Bedeutung des Plasma D-Dimer Spiegels bei Patienten mit Glioblastoma Multiforme – Ergebnisse einer Pilot Studie


Das Glioblastoma multiforme (GBM) ist der häufigste maligne Primärtumor des Zentralnervensystems und geht mit einer Aktivierung des Gerinnungssystems einher. Unklar in diesem Zusammenhang ist, ob D-Dimer, ein Fibrin-Spaltprodukt, mit der Tumoraktivität assoziiert ist und prognostische Bedeutung in Bezug auf das Gesamtüberleben hat. Wir untersuchten den Zusammenhang von Plasma D-Dimer Spiegeln und klinischen Endpunkten bei 23 Patienten mit histologisch verifiziertem GBM. Der Studieneinschluss erfolgte zwei bis drei Wochen nach neurochirurgischer Intervention und vor dem Beginn der adjuvanten Therapie (Radio-Chemotherapie). Innerhalb eines medianen Beobachtungszeitraums von 7,3 Monaten (Interquartilbereich, 3,5–22 Monate), starben 21 Patienten (91,3%). Erhöhte D-Dimer Plasmas Spiegel waren signifikant mit Gesamtüberleben assoziiert (log rank p = 0,002). Die Hazard Ratio für Patienten mit erhöhten D-Dimer Spiegeln lag bei 10.8 (95% Konfidenzintervall, 1,3–93,1; p = 0,03), verglichen mit Patienten mit niedrigeren Werten. Ähnliche, signifikante Ergebnisse fanden sich auch im Bezug auf das tumorprogressionsfreie Überleben (log rank p = 0.002). Erhöhte D-Dimer Spiegel war zusätzlich auch mit dem auftreten venöser Thromboembolien assoziiert (log rank p = 0,025). Bei Patienten mit GBM fanden sich Hinweise das D-Dimer Plasma Spiegel dem Überleben und der Tumorprogression assoziiert ist. Die Resultate vorliegender Pilot-Studie müssen anhand einer großen, prospektiven Studie bestätigt werden.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. DeAngelis LM. Brain tumors. N Engl J Med 2001;344:114–23PubMedCrossRefGoogle Scholar
  2. Hess KR, Broglio KR, Bondy ML. Adult glioma incidence trends in the United States, 1977–2000. Cancer 2004;101:2293–9.PubMedCrossRefGoogle Scholar
  3. Ohgaki H, Dessen P, Jourde B, et al. Genetic pathways to glioblastoma: a population-based study. Cancer Res 2004;64:6892–9.PubMedCrossRefGoogle Scholar
  4. Krex D, Klink B, Hartmann C, et al. Long-term survival with glioblastoma multiforme. Brain 2007;130:2596–606PubMedCrossRefGoogle Scholar
  5. Stupp R, Pavlidis N, Jelic S. ESMO Guidelines Task Force. ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of malignant glioma. Ann Oncol 2005;16(Suppl. 1):i64–5PubMedCrossRefGoogle Scholar
  6. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987–96PubMedCrossRefGoogle Scholar
  7. Marras LC, Geerts WH, Perry JR. The risk of venous thromboembolism is increased throughout the course of malignant glioma: an evidence-based review. Cancer 2000;89:640–6PubMedCrossRefGoogle Scholar
  8. Semrad TJ, O'Donnell R, Wun T, et al. Epidemiology of venous thromboembolism in 9489 patients with malignant glioma. J Neurosurg 2007;106:601–8PubMedCrossRefGoogle Scholar
  9. Goldenberg N, Kahn SR, Solymoss S. Markers of coagulation and angiogenesis in cancer-associated venous thromboembolism. J Clin Oncol 2003;21:4194–9PubMedCrossRefGoogle Scholar
  10. Wada H, Sase T, Yamaguchi M. Hypercoagulant states in malignant lymphoma. Exp Oncol 2005;27:179–85PubMedGoogle Scholar
  11. Rickles FR, Edwards RL. Activation of blood coagulation in cancer: Trousseau's syndrome revisited. Blood 1983;62:14–31PubMedGoogle Scholar
  12. Vukovich TC, Gabriel A, Schaeffer B, Veitl M, Matula C, Spiss CK. Hemostasis activation in patients undergoing brain tumor surgery. J Neurosurg 1997;87:508–11PubMedCrossRefGoogle Scholar
  13. Ay C, Vormittag R, Dunkler D, et al. D-Dimer and Prothrombin Fragment 1 + 2 Predict Venous Thromboembolism in Patients With Cancer: Results From the Vienna Cancer and Thrombosis Study. J Clin Oncol 2009;27:4124–9PubMedCrossRefGoogle Scholar
  14. Oya M, Akiyama Y, Yanagida T, et al. Plasma D-dimer level in patients with colorectal cancer: its role as a tumour marker. Surg Today 1998;28:373–8PubMedCrossRefGoogle Scholar
  15. Kilic M, Yoldas O, Keskek M, et al. Prognostic value of plasma D-dimer levels in patients with colorectal cancer. Colorectal Dis 2008;10:238–41.PubMedCrossRefGoogle Scholar
  16. Taguchi O, Gabazza EC, Yasui H, Kobayashi T, Yoshida M, Kobayashi H. Prognostic significance of plasma D-dimer levels in patients with lung cancer. Thorax 1997;52:563–5PubMedCrossRefGoogle Scholar
  17. Buccheri G, Torchio P, Ferrigno D. Plasma levels of D-dimer in lung carcinoma: clinical and prognostic significance. Cancer 2003;97:3044–52PubMedCrossRefGoogle Scholar
  18. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457–81CrossRefGoogle Scholar
  19. Haubold K, Rink M, Spath B, et al. Tissue factor procoagulant activity of plasma microparticles is increased in patients with early-stage prostate cancer. Thromb Haemost 2009;101:1147–55PubMedGoogle Scholar
  20. Toth B, Liebhardt S, Steinig K, et al. Platelet-derived microparticles and coagulation activation in breast cancer patients. Thromb Haemost 2008;100:663–9PubMedGoogle Scholar
  21. Sasayama T, Nishihara M, Kondoh T, Hosoda K, Kohmura E. MicroRNA-10b is overexpressed in malignant glioma and associated with tumor invasive factors, uPAR and RhoC. Int J Cancer 2009;125:1407–13PubMedCrossRefGoogle Scholar
  22. Norman PH, Thall PF, Purugganan RV, et al. A possible association between aprotinin and improved survival after radical surgery for mesothelioma. Cancer 2009;115:833–41PubMedCrossRefGoogle Scholar
  23. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005;352:997–1003.PubMedCrossRefGoogle Scholar
  24. Simanek R, Vormittag R, Hassler M, et al. Venous thromboembolism and survival in patients with high-grade glioma. Neuro Oncol 2007;9:89–95PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Matthias Hoke
    • 1
    Email author
  • Karin Dieckmann
    • 2
  • Renate Koppensteiner
    • 1
  • Martin Schillinger
    • 1
  • Christine Marosi
    • 3
  • Wolfgang Mlekusch
    • 1
  1. 1.Department of Internal Medicine II, Division of AngiologyAll Medical UniversityViennaAustria
  2. 2.Department of Radiotherapy and RadiobiologyAll Medical UniversityViennaAustria
  3. 3.Department Internal Medicine I, Division of OncologyAll Medical UniversityViennaAustria

Personalised recommendations